OpenURL Connection Search

Select item for more details and to access through your institution.

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Published in:
2000
By:
- Marrie TJ;
- Lau CY;
- Wheeler SL;
- Wong CJ;
- Vandervoort MK;
- Feagan BG;
- CAPITAL Study Investigators;
- Marrie, T J;
- Lau, C Y;
- Wheeler, S L;
- Wong, C J;
- Vandervoort, M K;
- Feagan, B G
Publication type:
journal article
A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY.
Published in:
Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 18, doi. 10.1093/jcag/gwab002.014
By:
- Feagan, B G;
- Loftus, E V;
- Danese, S;
- Vermeire, S;
- Sandborn, W J;
- Ritter, T;
- Mehta, R;
- Seidler, U;
- Seibold, F;
- Beales, I;
- Kim, H;
- McNally, J;
- Yun, C;
- Zhao, S;
- Liu, X;
- Tasset, C;
- Besuyen, R;
- Watanabe, M;
- Schreiber, S;
- Rogler, G
Publication type:
Article
A145 ORAL 5-ASA FOR INDUCTION AND MAINTENANCE OF REMISSION IN ULCERATIVE COLITIS.
Published in:
Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 288, doi. 10.1093/jcag/gwz006.144
By:
- Murray, A;
- Nguyen, T;
- Parker, C E;
- MacDonald, J K;
- Feagan, B G
Publication type:
Article
A130 SAFETY OF COMBINATION BIOLOGIC AND ANTI-REJECTION THERAPY POST-LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: LONDON ONTARIO EXPERIENCE.
Published in:
Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 260, doi. 10.1093/jcag/gwz006.129
By:
- Draiweesh, S Al;
- Ma, C;
- Alkhattabi, M;
- McDonald, C;
- Chande, N;
- Feagan, B G;
- Gregor, J C;
- Khanna, R;
- Marotta, P;
- Sandhu, A S;
- Qumosani, K;
- Teriaky, A;
- Brahmania, M;
- Jairath, V
Publication type:
Article
A96 ADALIMUMAB FOR MAINTENANCE OF REMISSION IN CROHN'S DISEASE.
Published in:
Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 191, doi. 10.1093/jcag/gwz006.095
By:
- Townsend, C M;
- Cepek, J;
- Abbass, M;
- Nguyen, T;
- Parker, C E;
- MacDonald, J K;
- Feagan, B G;
- Jairath, V;
- Khanna, R
Publication type:
Article
Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial.
Published in:
2000
By:
- Feagan, Brian G.;
- Wong, Cindy J.;
- Kirkley, Alexandra;
- Johnston, D.W.C.;
- Smith, Frank C.;
- Whitsitt, Paul;
- Wheeler, Susan L.;
- Lau, Catherine Y.;
- Feagan, B G;
- Wong, C J;
- Kirkley, A;
- Johnston, D W;
- Smith, F C;
- Whitsitt, P;
- Wheeler, S L;
- Lau, C Y
Publication type:
journal article
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms.
Published in:
Clinical Pharmacology & Therapeutics, 2012, v. 91, n. 4, p. 635, doi. 10.1038/clpt.2011.328
By:
- Ordás, I;
- Mould, D R;
- Feagan, B G;
- Sandborn, W J
Publication type:
Article
Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission.
Published in:
Alimentary Pharmacology & Therapeutics, 2007, v. 26, n. 7, p. 987, doi. 10.1111/j.1365-2036.2007.03455.x
By:
- SANDBORN, W. J.;
- FEAGAN, B. G.;
- LICHTENSTEIN, G. R.
Publication type:
Article
CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Published in:
Alimentary Pharmacology & Therapeutics, 2006, v. 23, n. 5, p. 617, doi. 10.1111/j.1365-2036.2006.02791.x
By:
- FEAGAN, B. G.;
- SANDBORN, W. J.;
- LICHTENSTEIN, G.;
- RADFORD‐SMITH, G.;
- PATEL, J.;
- INNES, A.
Publication type:
Article
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2005, v. 21, n. 4, p. 373, doi. 10.1111/j.1365-2036.2005.02336.x
By:
- Feagan, B. G.;
- Sandborn, W. J.;
- Baker, J. P.;
- Cominelli, F.;
- Sutherland, L. R.;
- Elson, C. O.;
- Salzberg, B. A.;
- Archambault, A.;
- Bernstein, C. N.;
- Lichtenstein, G. R.;
- Heath, P. K.;
- Cameron, S.;
- Hanauer, S. B.
Publication type:
Article
Mild to moderate Crohn's disease – defining the basis for a new treatment algorithm.
Published in:
Alimentary Pharmacology & Therapeutics, 2003, v. 18, n. 3, p. 263, doi. 10.1046/j.1365-2036.2003.01661.x
By:
- Sandborn, W. J.;
- Feagan, B. G.
Publication type:
Article
Systematic review: the effectiveness of budesonide therapy for Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2002, v. 16, n. 8, p. 1509, doi. 10.1046/j.1365-2036.2002.01289.x
By:
- Kane, S. V.;
- Schoenfeld, P.;
- Sandborn, W. J.;
- Tremaine, W.;
- Hofer, T.;
- Feagan, B. G.
Publication type:
Article
Review article: Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy.
Published in:
Alimentary Pharmacology & Therapeutics, 1997, v. 11, n. s3, p. 98, doi. 10.1111/j.1365-2036.1997.tb00814.x
By:
- HAMEDANI, R.;
- FELDMAN, R. D.;
- FEAGAN, B. G.
Publication type:
Article
An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 48, n. 3, p. 347, doi. 10.1111/apt.14853
By:
- Rieder, F.;
- Bettenworth, D.;
- Ma, C.;
- Parker, C. E.;
- Williamson, L. A.;
- Nelson, S. A.;
- van Assche, G.;
- Di Sabatino, A.;
- Bouhnik, Y.;
- Stidham, R. W.;
- Dignass, A.;
- Rogler, G.;
- Taylor, S. A.;
- Stoker, J.;
- Rimola, J.;
- Baker, M. E.;
- Fletcher, J. G.;
- Panes, J.;
- Sandborn, W. J.;
- Feagan, B. G.
Publication type:
Article
Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 48, n. 2, p. 114, doi. 10.1111/apt.14821
By:
- Ma, C.;
- Dutton, S. J.;
- Cipriano, L. E.;
- Singh, S.;
- Parker, C. E.;
- Nguyen, T. M.;
- Guizzetti, L.;
- Gregor, J. C.;
- Chande, N.;
- Hindryckx, P.;
- Feagan, B. G.;
- Jairath, V.
Publication type:
Article
Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 48, n. 1, p. 65, doi. 10.1111/apt.14794
By:
- Sandborn, W. J.;
- Rutgeerts, P.;
- Gasink, C.;
- Jacobstein, D.;
- Zou, B.;
- Johanns, J.;
- Sands, B. E.;
- Hanauer, S. B.;
- Targan, S.;
- Ghosh, S.;
- de Villiers, W. J. S.;
- Colombel, J.‐F.;
- Feagan, B. G.
Publication type:
Article
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 12, p. 1578, doi. 10.1111/apt.14672
By:
- Ma, C.;
- Guizzetti, L.;
- Panaccione, R.;
- Fedorak, R. N.;
- Pai, R. K.;
- Parker, C. E.;
- Nguyen, T. M.;
- Khanna, R.;
- Vande Casteele, N.;
- D'Haens, G.;
- Sandborn, W. J.;
- Feagan, B. G.;
- Jairath, V.
Publication type:
Article
Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE‐HSS)—an important first step. Authors’ reply.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 12, p. 1714, doi. 10.1111/apt.14658
By:
- Pai, R. K.;
- Bredenoord, A.;
- Feagan, B. G.;
- Jairath, V.
Publication type:
Article
Reliability of histologic assessment in patients with eosinophilic oesophagitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 7, p. 940, doi. 10.1111/apt.14559
By:
- Warners, M. J.;
- Ambarus, C. A.;
- Bredenoord, A. J.;
- Verheij, J.;
- Lauwers, G. Y.;
- Walsh, J. C.;
- Katzka, D. A.;
- Nelson, S.;
- van Viegen, T.;
- Furuta, G. T.;
- Gupta, S. K.;
- Stitt, L.;
- Zou, G.;
- Parker, C. E.;
- Shackelton, L. M.;
- D`Haens, G. R.;
- Sandborn, W. J.;
- Dellon, E. S.;
- Feagan, B. G.;
- Collins, M. H.
Publication type:
Article
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 2, p. 229, doi. 10.1111/apt.14421
By:
- Vande Casteele, N.;
- Feagan, B. G.;
- Vermeire, S.;
- Yassine, M.;
- Coarse, J.;
- Kosutic, G.;
- Sandborn, W. J.
Publication type:
Article
The development of a magnetic resonance imaging index for fistulising Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 5, p. 516, doi. 10.1111/apt.14190
By:
- Samaan, M. A.;
- Puylaert, C. A. J.;
- Levesque, B. G.;
- Zou, G. Y.;
- Stitt, L.;
- Taylor, S. A.;
- Shackelton, L. M.;
- Vandervoort, M. K.;
- Khanna, R.;
- Santillan, C.;
- Rimola, J.;
- Hindryckx, P.;
- Nio, C. Y.;
- Sandborn, W. J.;
- D'Haens, G.;
- Feagan, B. G.;
- Jairath, V.;
- Stoker, J.
Publication type:
Article
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 3, p. 292, doi. 10.1111/apt.14164
By:
- D'Haens, G. R.;
- Sandborn, W. J.;
- Zou, G.;
- Stitt, L. W.;
- Rutgeerts, P. J.;
- Gilgen, D.;
- Jairath, V.;
- Hindryckx, P.;
- Shackelton, L. M.;
- Vandervoort, M. K.;
- Parker, C. E.;
- Muller, C.;
- Pai, R. K.;
- Levchenko, O.;
- Marakhouski, Y.;
- Horynski, M.;
- Mikhailova, E.;
- Kharchenko, N.;
- Pimanov, S.;
- Feagan, B. G.
Publication type:
Article
Editorial: the impact of the placebo effect in Crohn's disease - author's reply.
Published in:
2017
By:
- Jairath, V.;
- Feagan, B. G.
Publication type:
Editorial
Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 5, p. 617, doi. 10.1111/apt.13913
By:
- Hindryckx, P.;
- Novak, G.;
- Vande Casteele, N.;
- Laukens, D.;
- Parker, C.;
- Shackelton, L. M;
- Narula, N.;
- Khanna, R.;
- Dulai, P.;
- Levesque, B. G;
- Sandborn, W. J;
- D'Haens, G.;
- Feagan, B. G.;
- Jairath, V.
Publication type:
Article
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 2, p. 264, doi. 10.1111/apt.13852
By:
- Feagan, B. G.;
- Patel, H.;
- Colombel, J.‐F.;
- Rubin, D. T.;
- James, A.;
- Mody, R.;
- Lasch, K.
Publication type:
Article
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2016, v. 44, n. 2, p. 157, doi. 10.1111/apt.13653
By:
- Sandborn, W. J.;
- Bhandari, B. R.;
- Fogel, R.;
- Onken, J.;
- Yen, E.;
- Zhao, X.;
- Jiang, Z.;
- Ge, D.;
- Xin, Y.;
- Ye, Z.;
- French, D.;
- Silverman, J. A.;
- Kanwar, B.;
- Subramanian, G. M.;
- McHutchison, J. G.;
- Lee, S. D.;
- Shackelton, L. M.;
- Pai, R. K.;
- Levesque, B. G.;
- Feagan, B. G.
Publication type:
Article
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 10, p. 1170, doi. 10.1111/apt.13398
By:
- Feagan, B. G.;
- Sandborn, W. J.;
- D'Haens, G.;
- Lee, S. D.;
- Allez, M.;
- Fedorak, R. N.;
- Seidler, U.;
- Vermeire, S.;
- Lawrance, I. C.;
- Maroney, A. C.;
- Jurgensen, C. H.;
- Heath, A.;
- Chang, D. J.
Publication type:
Article
Review article: pharmacological aspects of anti- TNF biosimilars in inflammatory bowel diseases.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 10, p. 1158, doi. 10.1111/apt.13402
By:
- Papamichael, K.;
- Van Stappen, T.;
- Jairath, V.;
- Gecse, K.;
- Khanna, R.;
- D'Haens, G.;
- Vermeire, S.;
- Gils, A.;
- Feagan, B. G.;
- Levesque, B. G.;
- Vande Casteele, N.
Publication type:
Article
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 10, p. 1200, doi. 10.1111/apt.13408
By:
- Jairath, V.;
- Khanna, R.;
- Zou, G. Y.;
- Stitt, L.;
- Mosli, M.;
- Vandervoort, M. K.;
- D'Haens, G.;
- Sandborn, W. J.;
- Feagan, B. G.;
- Levesque, B. G.
Publication type:
Article
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 5, p. 504, doi. 10.1111/apt.13291
By:
- Rutgeerts, P.;
- Feagan, B. G.;
- Marano, C. W.;
- Padgett, L.;
- Strauss, R.;
- Johanns, J.;
- Adedokun, O. J.;
- Guzzo, C.;
- Zhang, H.;
- Colombel, J.‐F.;
- Reinisch, W.;
- Gibson, P. R.;
- Sandborn, W. J.
Publication type:
Article
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 2, p. 188, doi. 10.1111/apt.13243
By:
- Rosario, M.;
- Dirks, N. L.;
- Gastonguay, M. R.;
- Fasanmade, A. A.;
- Wyant, T.;
- Parikh, A.;
- Sandborn, W. J.;
- Feagan, B. G.;
- Reinisch, W.;
- Fox, I.
Publication type:
Article
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 41, n. 1, p. 77, doi. 10.1111/apt.13001
By:
- Khanna, R.;
- Zou, G.;
- D'Haens, G.;
- Feagan, B. G.;
- Sandborn, W. J.;
- Vandervoort, M. K.;
- Rolleri, R. L.;
- Bortey, E.;
- Paterson, C.;
- Forbes, W. P.;
- Levesque, B. G.
Publication type:
Article
Letter: limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease - authors' reply.
Published in:
Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 1, p. 121, doi. 10.1111/apt.12817
By:
- Levesque, B. G.;
- Feagan, B. G.
Publication type:
Article
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 10, p. 1126, doi. 10.1111/apt.12733
By:
- Levesque, B. G.;
- Greenberg, G. R.;
- Zou, G.;
- Sandborn, W. J.;
- Singh, S.;
- Hauenstein, S.;
- Ohrmund, L.;
- Wong, C. J.;
- Stitt, L. W.;
- Shackelton, L. M.;
- King, D.;
- Lockton, S.;
- Ducharme, J.;
- Feagan, B. G.
Publication type:
Article
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 5, p. 447, doi. 10.1111/apt.12407
By:
- Khanna, R.;
- Sattin, B. D.;
- Afif, W.;
- Benchimol, E. I.;
- Bernard, E.‐J.;
- Bitton, A.;
- Bressler, B.;
- Fedorak, R. N.;
- Ghosh, S.;
- Greenberg, G. R.;
- Marshall, J. K.;
- Panaccione, R.;
- Seidman, E. G.;
- Silverberg, M. S.;
- Steinhart, A. H.;
- Sy, R.;
- Van Assche, G.;
- Walters, T. D.;
- Sandborn, W. J.;
- Feagan, B. G.
Publication type:
Article
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
Published in:
Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 10, p. 1143, doi. 10.1111/j.1365-2036.2011.04636.x
By:
- Feagan, B. G.;
- Hanauer, S. B.;
- Coteur, G.;
- Schreiber, S.
Publication type:
Article
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Published in:
Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 5, p. 541, doi. 10.1111/j.1365-2036.2010.04568.x
By:
- Feagan, B. G.;
- Sandborn, W. J.;
- Wolf, D. C.;
- Coteur, G.;
- Purcaru, O.;
- Brabant, Y.;
- Rutgeerts, P. J.
Publication type:
Article
Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study.
Published in:
Alimentary Pharmacology & Therapeutics, 2010, v. 31, n. 12, p. 1276, doi. 10.1111/j.1365-2036.2010.04303.x
By:
- FEAGAN, B. G.;
- REILLY, M. C.;
- GERLIER, L.;
- BRABANT, Y.;
- BROWN, M.;
- SCHREIBER, S.
Publication type:
Article
Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost–Utility Analysis.
Published in:
Advances in Therapy, 2021, v. 38, n. 12, p. 5737, doi. 10.1007/s12325-021-01957-7
By:
- Beauchemin, C.;
- Castonguay, A.;
- Chan, E. S.;
- Dellon, E. S.;
- Feagan, B. G.;
- Ma, C.;
- Waserman, S.;
- Cook, J.;
- Claveau, D.
Publication type:
Article

Found: 39